6971-26-2

Usage

Purine derivative

A modified version of the purine structure Purine is a heterocyclic aromatic organic compound, and 2,6-dichloro-9-phenyl-9H-purine is derived from it.

Potent antagonist of adenosine receptors

It effectively blocks the action of adenosine Adenosine is a nucleoside that plays a role in various physiological processes, including sleep, mood, and immune function.

Potential anti-inflammatory and analgesic medication

It may help reduce inflammation and relieve pain By blocking adenosine receptors, 2,6-dichloro-9-phenyl-9H-purine could potentially be used to alleviate pain and inflammation in various conditions.

Studied for treatment of neurological disorders and cancer

It has shown promise in targeting adenosine receptors for therapeutic purposes The compound's interaction with adenosine receptors may help in the treatment of neurological conditions and cancer by modulating immune responses and inflammation.

Therapeutic potential in modulating immune responses and inflammation

It may help regulate the immune system and reduce inflammation By targeting adenosine receptors, 2,6-dichloro-9-phenyl-9H-purine could potentially be used to control the immune system and inflammation in various diseases.

Further research needed

The biological and pharmacological properties are not yet fully understood More studies are required to determine the safety, efficacy, and potential applications of 2,6-dichloro-9-phenyl-9H-purine in treating various conditions.

Upstream product

• 5444-47-3 9-phenyl-3,9-dihydro-purine-2,6-dione 
• 66003-76-7 Diphenyliodonium triflate 
• 5451-40-1 2,6 dichloropurine 
• 103-72-0 phenyl isothiocyanate 
• 5444-47-3 9-phenyl-3,9-dihydro-purine-2,6-dione 
• 133973-91-8 9-phenyl-8-thio-uric acid 
• 1483-72-3 diphenyliodonium chloride 

Downstream Products

• 121193-64-4 9-phenyl-3,9-dihydro-purine-2,6-dithione 
• 115164-06-2 2-chloro-9-phenyl-1,9-dihydro-purin-6-one 
• 133973-94-1 (S)-β-<(9-phenyl-2-chloro-1H-purin-6-yl)amino>benzenepropanol 
• 133973-92-9 (R)-β-<(9-phenyl-2-chloro-1H-purin-6-yl)amino>benzenepropanol 
• 133973-95-2 (S)-β-[(2-propoxy-9-phenyl-1H-purin-6-yl)amino]benzenepropanol 
• 133973-93-0 (R)-β-[(2-propoxy-9-phenyl-1H-purin-6-yl)amino]benzenepropanol 

Relevant academic research and scientific papers

Management of Locally Excited States for Purine-based TADF Emitters: A Method to Reduce Device Efficiency Roll-Off

The programmed arylation of purine has been developed to construct a series of efficient thermally activated delayed fluorescent (TADF) materials. The corresponding organic light-emitting diodes (OLEDs) exhibit external quantum efficiency as high as 16.0% alongside small efficiency roll-off. Intriguingly, this work proves that the good management of localized states is an efficient way to reduce device efficiency roll-off and is crucial for the future design of high-performance OLEDs.

COMPOUNDS FOR TREATING CYSTIC FIBROSIS

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).

CuBr catalyzed C-N cross coupling reaction of purines and diaryliodonium salts to 9-arylpurines

CuBr was found to be an efficient catalyst for the C-N cross coupling reaction of purine and diaryliodonium salts. 9-Arylpurines were synthesized in excellent yields with short reaction times (2.5 h). The method represents an alternative to the synthesis of 9-arylpurines via Cu(ii) catalyzed C-N coupling reaction with arylboronic acids as arylating agents. The Royal Society of Chemistry 2011.

Selective adenosine reseptor compounds

Adenosine analogues which act selectively at adenosine receptors and which act in general as adenosine antagonists are disclosed. From in vitro studies it is known that specific physiological effects can be distinguished as a result of this selectivity an